Research programme: p38 MAP kinase inhibitors - Almirall

Drug Profile

Research programme: p38 MAP kinase inhibitors - Almirall

Alternative Names: p38α MAP inhibitors

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall S.A.
  • Class Aminopyridines; Cyclic N oxides; Naphthyridines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Spain (PO)
  • 09 Sep 2010 Pharmacodynamics data from preclinical studies in Rheumatoid Arthritis presented at the 21st International Symposium on Medicinal Chemistry (ISMC-2010)
  • 20 Aug 2009 Preclinical trials in Rheumatoid arthritis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top